These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

150 related items for PubMed ID: 15302230

  • 1. Additive effects of combined valsartan and spironolactone on cardiac aldosterone escape in spontaneously hypertensive rats.
    Liang YH, Wang JM, Zhou Y, Jiang XJ, Jiang H, Huang CX.
    Life Sci; 2004 Aug 27; 75(15):1871-8. PubMed ID: 15302230
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Transient prehypertensive treatment in spontaneously hypertensive rats: a comparison of spironolactone and losartan regarding long-term blood pressure and target organ damage.
    Baumann M, Hermans JJ, Janssen BJ, Peutz-Kootstra C, Witzke O, Heemann U, Smits JF, Boudier HA.
    J Hypertens; 2007 Dec 27; 25(12):2504-11. PubMed ID: 17984673
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Role of aldosterone in angiotensin II-induced cardiac and aortic inflammation, fibrosis, and hypertrophy.
    Neves MF, Amiri F, Virdis A, Diep QN, Schiffrin EL, CIHR Multidisciplinary Research Group on Hypertension.
    Can J Physiol Pharmacol; 2005 Nov 27; 83(11):999-1006. PubMed ID: 16391708
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Impact of aldosterone receptor blockade on the deleterious cardiac effects of adrenergic activation in hypertensive rats.
    Veliotes DG, Norton GR, Correia RJ, Strijdom H, Badenhorst D, Brooksbank R, Woodiwiss AJ.
    J Cardiovasc Pharmacol; 2010 Aug 27; 56(2):203-11. PubMed ID: 20531215
    [Abstract] [Full Text] [Related]

  • 10. Influence of Valsartan on myocardial apoptosis in spontaneously hypertensive rats.
    Li W, Sun N, Liu W, Chen Y, Yu Y.
    Chin Med J (Engl); 2002 Mar 27; 115(3):364-6. PubMed ID: 11940365
    [Abstract] [Full Text] [Related]

  • 11. Genomic and nongenomic effects of aldosterone in the rat heart: why is spironolactone cardioprotective?
    Chai W, Garrelds IM, Arulmani U, Schoemaker RG, Lamers JM, Danser AH.
    Br J Pharmacol; 2005 Jul 27; 145(5):664-71. PubMed ID: 15834444
    [Abstract] [Full Text] [Related]

  • 12. Aldosterone breakthrough during angiotensin II receptor antagonist therapy in stroke-prone spontaneously hypertensive rats.
    Naruse M, Tanabe A, Sato A, Takagi S, Tsuchiya K, Imaki T, Takano K.
    Hypertension; 2002 Jul 27; 40(1):28-33. PubMed ID: 12105134
    [Abstract] [Full Text] [Related]

  • 13. Role of the renin-angiotensin-aldosterone system in collecting duct-derived endothelin-1 regulation of blood pressure.
    Ge Y, Huang Y, Kohan DE.
    Can J Physiol Pharmacol; 2008 Jun 27; 86(6):329-36. PubMed ID: 18516095
    [Abstract] [Full Text] [Related]

  • 14. Changes in the composition of the thoracic aortic wall in spontaneously hypertensive rats treated with losartan or spironolactone.
    Han WQ, Wu LY, Zhou HY, Zhang J, Che ZQ, Wu YJ, Liu JJ, Zhu DL, Gao PJ.
    Clin Exp Pharmacol Physiol; 2009 May 27; 36(5-6):583-8. PubMed ID: 19673944
    [Abstract] [Full Text] [Related]

  • 15. Spironolactone exhibits direct renoprotective effects and inhibits renal renin-angiotensin-aldosterone system in diabetic rats.
    Taira M, Toba H, Murakami M, Iga I, Serizawa R, Murata S, Kobara M, Nakata T.
    Eur J Pharmacol; 2008 Jul 28; 589(1-3):264-71. PubMed ID: 18582458
    [Abstract] [Full Text] [Related]

  • 16. Reduction of QTc dispersion by the angiotensin II receptor blocker valsartan may be related to its anti-oxidative stress effect in patients with essential hypertension.
    Miyajima K, Minatoguchi S, Ito Y, Hukunishi M, Matsuno Y, Kakami M, Kawasaki M, Nishigaki K, Takemura G, Fujiwara H.
    Hypertens Res; 2007 Apr 28; 30(4):307-13. PubMed ID: 17541209
    [Abstract] [Full Text] [Related]

  • 17. [Mechanism of reversion of myocardial interstitial fibrosis in diabetic cardiomyopathy by valsartan].
    Zhong M, Zhang Y, Miao Y, Li L, Gong HP, Ma X, Sun H, Zhang W.
    Zhonghua Yi Xue Za Zhi; 2006 Jan 24; 86(4):232-6. PubMed ID: 16677501
    [Abstract] [Full Text] [Related]

  • 18. Combined effects of low-dose spironolactone and captopril therapy in a rat model of genetic hypertrophic cardiomyopathy.
    de Resende MM, Kriegel AJ, Greene AS.
    J Cardiovasc Pharmacol; 2006 Dec 24; 48(6):265-73. PubMed ID: 17204904
    [Abstract] [Full Text] [Related]

  • 19. Anti-inflammatory effects of AT1 receptor blockade provide end-organ protection in stroke-prone rats independently from blood pressure fall.
    Sironi L, Gelosa P, Guerrini U, Banfi C, Crippa V, Brioschi M, Gianazza E, Nobili E, Gianella A, de Gasparo M, Tremoli E.
    J Pharmacol Exp Ther; 2004 Dec 24; 311(3):989-95. PubMed ID: 15302895
    [Abstract] [Full Text] [Related]

  • 20. Effect of simvastatin given alone and in combination with valsartan or enalapril on blood pressure and the structure of mesenteric resistance arteries and the basilar artery in the genetically hypertensive rat model.
    Ledingham JM, Laverty R.
    Clin Exp Pharmacol Physiol; 2005 Dec 24; 32(1-2):76-85. PubMed ID: 15730439
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.